BPA
ALXO icon

Beacon Pointe Advisors’s ALX Oncology ALXO Stock Holding History

Beacon Pointe Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.9K Hold
12,500
– – ﹤0.01% 1907
2026
Q1 		$25.1K Buy
+12,500
New +$23.8K ﹤0.01% 1819

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Beacon Pointe Advisors's ALXO Position: Q2 2026 in Review

Beacon Pointe Advisors held its ALX Oncology (ALXO) position steady in Q2 2026 at 12,500 shares worth $25.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1907.

Beacon Pointe Advisors first reported a position in ALXO in Q1 2026 and has held it in 2 quarters since. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Beacon Pointe Advisors held 12,500 shares of ALX Oncology worth $25.9K as of Q2 2026.
  • Beacon Pointe Advisors left its ALX Oncology share count unchanged in Q2 2026.
  • ALX Oncology made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1907 holding.
  • Beacon Pointe Advisors first reported a position in ALX Oncology in Q1 2026 and has held it in 2 quarters since.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.